EquiReason

EquiReason research coverage

PTC Therapeutics, Inc. PTCT

Healthcare · Biotechnology

24quarters analysed
12SEC filings read
8segments identified
12institutional managers tracked

Segments it reports

The business segments PTC Therapeutics, Inc. reports in its own SEC filings.

  • Life Science Segment

Product lines it reports

The product and service lines PTC Therapeutics, Inc. breaks its revenue into.

  • Collaboration And License Revenue
  • Royalty
  • Translarna1
  • Emflaza
  • Upstaza And Kebilidi
  • Other Products

Where its revenue is reported

The geographies PTC Therapeutics, Inc. reports revenue for. How much comes from each is in the product.

  • United States
  • Russia
  • Brazil

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements27
  • Quarterly metric series12
  • Business segments8
  • SEC filings12
  • Deals and transactions3
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks8
  • Estimate revisions11
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series24
  • Cash flow series24
  • Earnings series24
  • Operating cash flow series24
  • Guidance changesnot found
  • Margin seriesnot found
  • Per-share seriesnot found

This page says how much of PTC Therapeutics, Inc. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open PTCT in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

PTC Therapeutics, Inc. (PTCT) — research coverage | EquiReason